Interní Med. 2015; 17(1): 23-25

Dialysis-related amyloidosis

MUDr.Radoslav Roman1, doc.MUDr.Kamil Ševela, CSc.1, MUDr.Darja Krusová, Ph.D.1, MUDr.Jan Svojanovský, Ph.D.1, prof.MUDr.Miroslav Souček, CSc.1, MUDr.Lukáš Pazourek2
1 II. interní klinika FN u sv. Anny v Brně
2 Ortopedická klinika FN u sv. Anny v Brně

Dialysis-related amyloidosis is a serious complication in patients receiving long-term dialysis. It is caused by formation of β2-mikroglobulin

in amyloid deposits. Because of its affinity to osteoarticular tissue clinical manifestation includes carpal tunnel syndrome, joint arthropathy,

bone cysts, destructive spondylarthropathy, and, in rare cases, also systemic disorders. Risk factors are long term hemodialysis,

early onset of hemodialysis, treatment with low purity dialysate and absence of using high-flux membranes. Definitive diagnosis is made

by histologic examination material by congo red staining and immunostaining of amyloid deposits with labeled anti-h2-m antibody.

Clinical therapeutic strategies for dialysis related amyloidosis include dialysis, medical or surgical therapy, and renal transplantation.

Keywords: dialysis related amyloidosis, β2-microglobulin, high-flux dialysis membrane

Published: February 27, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roman R, Ševela K, Krusová D, Svojanovský J, Souček M, Pazourek L. Dialysis-related amyloidosis. Interní Med. 2015;17(1):23-25.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int. 2014; 18(1): 136-141. Go to original source... Go to PubMed...
    2. Koch KM, Harrlngton JT. Dialysis-related amyloidosis. 1992; 41: 1416-1429. Go to original source...
    3. Jadoul M, Garbar C, Vanholder R, Sennesael J, Michel C, Robert A, et al. Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. Kidney Int. 1998; 54(3): 956-959. Go to original source... Go to PubMed...
    4. Suguru Yamamoto JJKHM and, Narita I. Amyloidosis [Internet]. Feng D, editor. InTech; 2013 [cited 2014 Dec 20]. Available from: http://www.intechopen.com/books/amyloidosis/dialysis-related-amyloidosis-pathogenesis-and-clinical-features-in-patients-undergoing-dialysis-trea. Go to original source...
    5. Eichner T, Radford SE. Understanding the complex mechanisms of ?2-microglobulin amyloid assembly. FEBS J. 2011; 278(20): 3868-3883. Go to original source... Go to PubMed...
    6. Taylor G. The interaction between fibrillar beta-2 microglobulin and serum amyloid P component. University of Southampton; 2011. p. 284.
    7. Farrell J, Bastani B. Beta 2-microglobulin amyloidosis in chronic dialysis patients: a case report and review of the literature. J Am Soc Nephrol. 1997; 8(3): 509-514. Go to original source... Go to PubMed...
    8. Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial. 2014; 24(1): 1-4. Go to original source...
    9. Ledebo I. Ultrapure dialysis fluid-direct and indirect benefits in dialysis therapy. Blood Purif. 2004; 22(suppl 2): 20-25. Go to original source... Go to PubMed...
    10. Uji Y, Motomiya Y, Ando Y. Effect of heparin on conformation of the ?2-microglobulin molecule. Ther Apher Dial. 2012; 16(2): 159-162. Go to original source... Go to PubMed...
    11. Klinkmann H, Buscaroli A, Stefoni S. ?2-Microglobulin and Low-Flux Synthetic Dialyzers. 1998; 22(7): 585-590. Go to original source...
    12. Heegaard NHH. beta(2)-microglobulin: from physiology to amyloidosis. Amyloid. Informa UK Ltd UK; 2009; 16(3): 151-713. Go to original source...
    13. Danesh F, Ho LT. Dialysis-Related Amyloidosis: History and Clinical Manifestations. Semin Dial. 2008; 14(2): 80-85. Go to original source...
    14. Dru TB. Nephrology Dialysis Transplantation Dialysis-related amyloidosis. 1998; 58-64. Go to original source... Go to PubMed...
    15. Kiss E, Keusch G, Zanetti M, Jung T, Schwarz A, Schocke M, et al. Dialysis-related amyloidosis revisited. AJR Am J Roentgenol. 2005; 185(6): 1460-1467. Go to original source... Go to PubMed...
    16. Lee KS, van Holsbeeck MT, Abbud A. Atypical rapid progression of osteoarticular amyloidosis involving the hip in a patient on hemodialysis using polyacrylonitrile membranes. Skeletal Radiol. 2010; 39(1): 79-83. Go to original source... Go to PubMed...
    17. Yamamoto S, Gejyo F. Historical background and clinical treatment of dialysis-related amyloidosis. Biochim Biophys Acta. 2005; 1753(1): 4-10. Go to original source... Go to PubMed...
    18. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Michael Lazarus J, et al. Utility of highresolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum. 1992; 35(8): 926-932. Go to original source...
    19. Cardinal E EM, Benson D. Amyloidosis of the Shoulder in Patients on Chronic Hemodialysis: Findings. Am J Roentgenol. 1996;(166): 153-156. Go to original source...
    20. Lanteri M, Ptasznik R, Hennesy O, Constable L. Ultrasound assessment of large joint amyloidosis in haemodialysis. 2000; 45-50. Go to original source...
    21. Sommer R, Valen GJ, Ori Y, Weinstein T, Katz M, Hendel D, et al. Sonographic features of dialysis-related amyloidosis of the shoulder. J Ultrasound Med. 2000; 19(11): 765-770. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.